Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study

Table 2 Outcome of the 36 children with philadelphia chromosome-positive acute lymphoblastic leukemia as a function of early characteristics

	No patients	No CR (%)	p	5 yr-EFS	p	5 yr-OS	p
Whole cohort	N = 36	26 (72%)		33.3 ± 7.9		47.2 ± 8.3
Inclusion period
< July, 1996	15	9 (60%)		20 ± 10		33 ± 12
> July, 1996	21	17 (81%)	0.26	43 ± 11	0.13	57 ± 11	0.31
Age (years)
<10	23	20 (87%)		48 ± 10		61 ± 10
≥ 10	13	6 (46%)	0.018	15 ± 10	0.01	23 ± 12	0.006
WBC (/mm ³ )
<50,000	21	17 (81%)		33 ± 10
≥ 50,000	15	9 (60%)	0.26	33 ± 12	0.54		0.91
<100,000	26	22 (85%)		42 ± 10		58 ± 10
≥ 100,000	10	4 (40%)	0.014	10 ± 9	0.003	20 ± 13	0.03
Response to steroid (+3 drug intra-thecal injection) at D8
poor (≥ 1000 blasts/mm³)	5	2 (40%)		20 ± 18		20 ± 18
good(<1000 blasts/mm³)	31	24 (77%)	0.12	35 ± 9	0.33	52 ± 9	0.19
Response to chemotherapy evaluated on D21
M1(≤ 5% blasts)	21	20 (95%)		43 ± 11		62 ± 11
M2+M3 (>5%–25% and >25% blasts)	15	6 (40%)	0.0004	20 ± 10	0.18	27 ± 11	0.06
Age, D21 response and WBC
Age<10 and D21 M1 and WBC count<100,000	14	14 (100%)		57 ± 13		79 ± 11
Others	22	12 (55%)	0.003	18 ± 8	0.002	27 ± 9	0.003

WBC = white blood cell; D = day; Response to steroid is evaluated in peripheral blood on day 8; Response to chemotherapy is evaluated in bone marrow on day 21